February 8, 2018 / 12:04 PM / 10 months ago

BRIEF-Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Heterozygous Familial Hypercholesterolemia

Feb 8 (Reuters) - Madrigal Pharmaceuticals Inc:

* MADRIGAL’S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)

* MADRIGAL PHARMACEUTICALS- STATISTICALLY SIGNIFICANT IMPROVEMENT ACHIEVED IN REDUCTION OF LDL CHOLESTEROL (LDL-C) WITH MGL-3196 COMPARED TO PLACEBO

* MADRIGAL PHARMACEUTICALS INC - MGL-3196 WAS WELL TOLERATED IN THE TRIAL AS COMPARED TO PLACEBO

* MADRIGAL PHARMACEUTICALS- LDL-C LOWERING WAS 28.5% IN MGL-3196 TREATED VERSUS PLACEBO IN PRESPECIFIED GROUP OF PATIENTS WHO DIDNT TOLERATE HIGH INTENSITY STATIN DOSES

* MADRIGAL PHARMACEUTICALS- THERE WERE 2 SERIOUS ADVERSE EVENTS IN STUDY, BOTH UNRELATED TO TREATMENT, ONE IN A PLACEBO AND ONE IN A DRUG-TREATED PATIENT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below